- Home
- RDCM vs PLX Comparison
RDCM vs PLX Comparison
Compare RDCM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | PLX |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 207.1M |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RDCM | PLX |
|---|---|---|
| Price | $10.16 | $2.56 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 43.7K | ★ 836.2K |
| Earning Date | 11-11-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $16.35 | ★ $9.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $1.65 |
| 52 Week High | $16.74 | $3.19 |
Technical Indicators
Market Signals| Indicator | RDCM | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 42.44 |
| Support Level | $10.07 | $2.21 |
| Resistance Level | $10.48 | $2.75 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 43.86 | 19.67 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.